1. Class action notice issued for Caribou Biosciences shareholders. 2. Allegations include false claims about CB-010's safety and efficacy. 3. Concerns raised over Caribou's cash and liquidity for operations. 4. Misleading statements may significantly impact Caribou's business. 5. Deadline to register for lead plaintiff is February 24, 2025.
The allegations of misleading statements can severely undermine investor confidence. Similar past cases show stock values collapsing after similar lawsuits.
The class action lawsuit raises serious concerns about Caribou's credibility and stock valuation. Such legal matters can lead to direct financial implications.
Upcoming legal challenges and claims can quickly affect stock performance. Historically, legal issues impact stock prices immediately.
The Gross Law Firm issues the following notice to shareholders of Caribou Biosciences, Inc. (NASDAQ: CRBU).
Shareholders who purchased shares of CRBU during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
July 14, 2023 to July 16, 2024
The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that:
(i) they had overstated CB-010's safety, efficacy, and durability relative to approved autologous CAR-T cell therapies in treating patients with r/r B-NHL and/or LBCL, as well as CB-010's overall clinical results and commercial prospects;
(ii) Caribou was at significant risk of having insufficient cash, liquidity, and/or other capital to fund its current business operations, including preclinical research activities associated with the allogeneic CAR-NK platform;
(iii) all the foregoing was likely to have a significant negative impact on Caribou's business and operations; and
(iv) as a result, defendants' public statements were materially false and misleading at all relevant times.
February 24, 2025. Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/caribou-biosciences-inc-loss-submission-form/?id=127841&from=4
Once you register as a shareholder who purchased shares of CRBU during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is February 24, 2025. There is no cost or obligation to you to participate in this case.
The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: info@grosslawfirm.com
Phone: (646) 453-8903